---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116329"
form_type: "8-K"
ticker: null
cik: "0000827871"
company_name: "EAGLE PHARMACEUTICALS, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:32:12.307541+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eagle Pharmaceuticals appoints Christopher Krawtschuk as CFO effective Nov 11, 2024

## Summary
- Christopher Krawtschuk named CFO, effective Nov 11; Steven Ratoff steps down as interim CFO, remains director.
- Krawtschuk previously CFO/treasurer at bluebird bio, CFO at Jubilant Pharma, U.S. CFO at Morphosys.
- Offer letter: $525k base salary, 50% target bonus, $150k signing bonus, 100k performance-vesting RSUs tied to listing and SEC filings.
- Shares trade on OTC Expert Market since Oct 4; 13,023,123 shares outstanding as of Oct 30.

## SEC filing metadata
- accession: 0001104659-24-116329
- form_type: 8-K
- cik: 0000827871
- company_name: EAGLE PHARMACEUTICALS, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/827871/000110465924116329/0001104659-24-116329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/827871/000110465924116329/tm2427095d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116329
- JSON: https://secwatch.observer/filing/0001104659-24-116329.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116329.txt

## Key facts
- Executive change
  Steven Ratoff changed role as Interim Chief Financial Officer at EAGLE PHARMACEUTICALS, INC..
  - Action: stepped down
  - Role: Interim Chief Financial Officer
  source text: In connection with Mr. Krawtschuk’s appoinment, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, Steven Ratoff, stepped down from serving in such capacities on the Effective Date and will remain as a director on the Company’s board of directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/827871/000110465924116329/0001104659-24-116329-index.htm
- Executive change
  Christopher Krawtschuk was appointed as Chief Financial Officer at EAGLE PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On November 8, 2024, the Board of Directors (the “Board”) of Eagle Pharmaceuticals, Inc. (the “Company”) appointed Christopher Krawtschuk to serve as the Company’s Chief Financial Officer, and designated Mr. Krawtschuk as its principal financial officer and principal accounting officer, each effective November 11, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/827871/000110465924116329/0001104659-24-116329-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.